Freezing UK Statutory Scheme Rebate Could Cost UK Government Over £15m
Executive Summary
Accepting the pharmaceutical industry’s request to keep the statutory scheme rebate rate at its current rate this year could cost the government dearly, but raising it as planned could be detrimental for UK life sciences.